Glial GABA transporters as modulators of inhibitory signalling in epilepsy and stroke

Advances in Neurobiology

Volumn 16, Issue , 2017, Pages 137-167

  Lie, Maria E K ^a   Al Khawaja, Anas ^a   Damgaard, Maria ^a   Haugaard, Anne S ^a   Schousboe, Arne ^a   Clarkson, Andrew N ^b,c   Wellendorph, Petrine ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BGT1; Epilepsy; GABAA receptors; GAT; GAT1; GAT3; Ischemic stroke; Tonic inhibition

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID CARRIER; BICUCULLINE; DIAZEPAM; GABA TRANSPORTER 1; GABA TRANSPORTER 3; GABOXADOL; HYPERTONIC SOLUTION; ISATIN; PICROTOXIN; TIAGABINE;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EPILEPSY; EPILEPTOGENESIS; HUMAN; MORTALITY; NERVE CELL PLASTICITY; NEUROPROTECTION; PATHOPHYSIOLOGY; PHYLOGENY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; ANIMAL; GLIA; METABOLISM;

ANIMALS; EPILEPSY; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; NEUROGLIA; STROKE;

EID: 85028063755     PISSN: 21905215     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-55769-4_7     Document Type: Chapter

References (189)

1. Akbar MT, Rattray M, Williams RJ, Chong NWS, Meldrum BS. Reduction of GABA and glutamate transporter messenger RNAs in the severe-seizure genetically epilepsy-prone rat. Neuroscience. 1998;85(4):1235–51.
2. Al-Khawaja A, Petersen JG, Damgaard M, Jensen MH, Vogensen SB, Lie MEK, et al. Pharmacological identification of a guanidine-containing β-alanine analogue with low micromolar potency and selectivity for the betaine/GABA transporter 1 (BGT1). Neurochem Res. 2014;39(10):1988–96.
3. Anderson M, Burda J, Ren Y, Ao Y, O’Shea T, Kawaguchi R, et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature. 2016;532(7598):195–200.
4. André V, Marescaux C, Nehlig A, Fritschy JM. Alterations of hippocampal GABAergic system contribute to development of spontaneous recurrent seizures in the rat lithium-pilocarpine model of temporal lobe epilepsy. Hippocampus. 2001;11(4):452–68.
5. Arellano JI, Muñoz A, Ballesteros-Yáñez I, Sola RG, DeFelipe J. Histopathology and reorganization of chandelier cells in the human epileptic sclerotic hippocampus. Brain. 2004;127(1):45–64.
6. Aronica E, Redeker S, Boer K, Spliet WGM, van Rijen PC, Gorter JA, et al. Inhibitory networks in epilepsy-associated gangliogliomas and in the perilesional epileptic cortex. Epilepsy Res. 2007;74(1):33–44.
7. A receptors. Neuropharmacology. 2006;51(6):1023–9.
8. Baldwin HA, Williams JL, Snares M, Ferreira T, Cross AJ, Green AR. Attenuation by chlorme-thiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat. Br J Pharmacol. 1994 May;112(1):188–94.
9. A receptors: form, pharmacology, and function. J Neurosci. 2009;29(41):12757–63.
10. Berkovic SF, Mulley JC, Scheffer IE, Petrou S. Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci. 2006;29(7):391–7.
11. B receptors. Physiol Rev. 2004;84(3):835–67.
12. Bhattacharya P, Pandey AK, Paul S, Patnaik R. Alleviation of glutamate mediated neuronal insult by piroxicam in rodent model of focal cerebral ischemia: a possible mechanism of GABA agonism. J Physiol Biochem. 2014;70(4):901–13.
13. Blicher JU, Near J, Næss-Schmidt E, Stagg CJ, Johansen-Berg H, Nielsen JF, et al. GABA levels are decreased after stroke and GABA changes during rehabilitation correlate with motor improvement. Neurorehabil Neural Repair. 2015;29(3):278–86.
14. Bolvig T, Larsson OM, Pickering DS, Nelson N, Falch E, Krogsgaard-Larsen P, et al. Action of bicyclic isoxazole GABA analogues on GABA transporters and its relation to anticonvulsant activity. Eur J Pharmacol. 1999;375(1–3):367–74.
15. Borden LA, Caplan MJ. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int. 1996;29(4):335–56.
16. Borden LA, Smith KE, Gustafson EL, Branchek TA, Weinshank RL. Cloning and expression of a betaine/GABA transporter from human brain. J Neurochem. 1995;64(3):977–84.
17. A-receptor expression in a mouse model of mesial temporal lobe epilepsy. Hippocampus. 2000;10(3):305–24.
18. A receptors: their function in the CNS and implications for disease. Neuron. 2012;73(1):23–34.
19. Brown CE, Aminoltejari K, Erb H, Winship IR, Murphy TH. In vivo voltage-sensitive dye imaging in adult mice reveals that somatosensory maps lost to stroke are replaced over weeks by new structural and functional circuits with prolonged modes of activation within both the peri-infarct zone and distant sites. J Neurosci. 2009;29(6):1719–34.
20. Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron. 2014;81(2):229–48.
21. Calcagnotto ME, Paredes MF, Baraban SC. Heterotopic neurons with altered inhibitory synaptic function in an animal model of malformation-associated epilepsy. J Neurosci. 2002;22(17): 7596–605.
22. Calcagnotto ME, Paredes MF, Tihan T, Barbaro NM, Baraban SC. Dysfunction of synaptic inhibition in epilepsy associated with focal cortical dysplasia. J Neurosci. 2005;25(42):9649–57.
23. Campbell AM, Holmes O. Bicuculline epileptogenesis in the rat. Brain Res. 1984;323(2):239–46.
24. Carmichael ST. Brain excitability in stroke: the yin and yang of stroke progression. Arch Neurol. 2012;69(2):161–7.
25. Chen F, Suzuki Y, Nagai N, Jin L, Yu J, Wang H, et al. Rodent stroke induced by photochemical occlusion of proximal middle cerebral artery: evolution monitored with MR imaging and histopathology. Eur J Radiol. 2007;63(1):68–75.
26. Chen Xu W, Yi Y, Qiu L, Shuaib A. Neuroprotective activity of tiagabine in a focal embolic model of cerebral ischemia. Brain Res. 2000;874(1):75–7.
27. Chiu C-S, Brickley S, Jensen K, Southwell A, Mckinney S, Cull-Candy S, et al. GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci. 2005;25(12):3234–45.
28. Clarkson AN. Perisynaptic GABA receptors the overzealous protector. Adv Pharmacol Sci. 2012;2012:708428.
29. Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature. 2010;468(7321): 305–9.
30. Clausen RP, Moltzen EK, Perregaard J, Lenz SM, Sanchez C, Falch E, et al. Selective inhibitors of GABA uptake: synthesis and molecular pharmacology of 4-N-methylamino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol analogues. Bioorg Med Chem. 2005;13(3):895–908.
31. A receptor. J Neurosci. 2002;22(13):5572–80.
32. Conti F, Melone M, De Biasi S, Minelli A, Brecha NC, Ducati A. Neuronal and glial localization of GAT-1, a high-affinity γ-aminobutyric acid plasma membrane transporter, in human cerebral cortex: with a note on its distribution in monkey cortex. J Comp Neurol. 1998;396(1):51–63.
33. Conti F, Minelli A, Melone M. GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain Res Rev. 2004;45(3):196–212.
34. Conti F, Zuccarello LV, Barbaresi P, Minelli A, Brecha NC, Melone M. Neuronal, glial, and epithelial localization of gamma-aminobutyric acid transporter 2, a high-affinity gamma-aminobutyric acid plasma membrane transporter, in the cerebral cortex and neighboring structures. J Comp Neurol. 1999;409(3):482–94.
35. A inhibition in typical absence epilepsy. Nat Med. 2009;15(12):1392–8.
36. B receptor results in neuroprotection during in vitro ischemia. Stroke. 2004;35(2):596–600.
37. Curtis DR, Duggan AW, Felix D, Johnston G. GABA, bicuculline and central inhibition. Nature. 1970;226(5252):1222–4.
38. Dalby NO. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology. 2000;39(12):2399–407.
39. Dalby NO. Inhibition of γ-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. Eur J Pharmacol. 2003;479(1–3):127–37.
40. Dalby NO, Thomsen C, Fink-Jensen A, Lundbeck J, Søkilde B, Man CM, et al. Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res. 1997;28(1):51–61.
41. Damgaard M, Haugaard AS, Al-Khawaja A, Lie MEK, Wellendorph P, Clausen RP, et al. Development of non-GAT1 selective GABA uptake inhibitors. In: Ortega A, Schousboe A, editors. Glial amino acid transporters. Cham: Springer; in press.
42. Damgaard M, Al-Khawaja A, Vogensen SB, Jurik A, Sijm M, Lie MEK, et al. Identification of the first highly subtype-selective inhibitor of human GABA transporter GAT3. ACS Chem Neurosci. 2015;6(9):1591–9.
43. Das N, Dhanawat M, Shrivastava SK. An overview on antiepileptic drugs. Drug Discov Ther. 2012;6(4):178–93.
44. Dhar TGM, Borden LA, Tyagarajan S, Smith KE, Branchek TA, Weinshank RL, et al. Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT- 3. J Med Chem. 1994;37(15):2334–42.
45. Dobkin BH. Training and exercise to drive poststroke recovery. Nat Clin Pract Neurol. 2008;4(2):76–85.
46. Dobkin BH, Dorsch A. New evidence for therapies in stroke rehabilitation. Curr Atheroscler Rep. 2013;15(6):331.
47. Doi T, Ueda Y, Nagatomo K, Willmore LJ. Role of glutamate and GABA transporters in development of pentylenetetrazol-kindling. Neurochem Res. 2009;34(7):1324–31.
48. +++-induced epileptic rats. Mol Brain Res. 2005;142(2):91–6.
49. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008 Sep;55(3):310–8.
50. During MJ, Ryder KM, Spencer DD. Hippocampal GABA transporter function in temporal-lobe epilepsy. Nature. 1995;376(6536):174–7.
51. Emberson J, Lees K, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;385(9958):1929–35.
52. Engelborghs S, D’Hooge R, De Deyn PP. Pathophysiology of epilepsy. Acta Neurol Belg. 2000;100(4):201–13.
53. A receptors. Adv Pharmacol Sci. 2011;2011:1–12.
54. Esclapez M, Houser CR. Up-regulation of GAD65 and GAD67 in remaining hippocampal GABA neurons in a model of temporal lobe epilepsy. J Comp Neurol. 1999;412(3):488–505.
55. A receptors. Nat Rev Neurosci. 2005;6(3):215–29.
56. Fink-Jensen A, Suzdak PD, Swedberg MDB, Judge ME, Hansen L, Nielsen PG. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol. 1992;220(2–3):197–201.
57. Frahm C, Haupt C, Weinandy F, Siegel G, Bruehl C, Witte OW. Regulation of GABA transporter mRNA and protein after photothrombotic infarct in rat brain. J Comp Neurol. 2004;478(2):176–88.
58. Freichel C, Potschka H, Ebert U, Brandt C, Löscher W. Acute changes in the neuronal expression of GABA and glutamate decarboxylase isoforms in the rat piriform cortex following status epilepticus. Neuroscience. 2006;141(4):2177–94.
59. Fu CY, He XY, Li XF, Zhang X, Huang ZW, Li J, et al. Nefiracetam attenuates pro-inflammatory cytokines and GABA transporter in specific brain regions of rats with post-ischemic seizures. Cell Physiol Biochem. 2015;37(5):2023–31.
60. Gastaut H, Naquet R, Poire R, Tassinari C. Treatment of status epilepticus with diazepam (Valium). Epilepsia. 1965;6:167–82.
61. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008;55(3):363–89.
62. Gonsalves SF, Twitchell B, Harbaugh RE, Krogsgaard-Larsen P, Schousboe A. Anticonvulsant activity of the glial GABA uptake inhibitor, THAO, in chemical seizures. Eur J Pharmacol. 1989;168(2):265–8.
63. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39(9):1483–94.
64. Héja L, Barabas P, Nyitrai G, Kekesi KA, Lasztoczi B, Toke O, et al. Glutamate uptake triggers transporter-mediated GABA release from astrocytes. PLoS One. 2009;4(9):e7153
65. Héja L, Nyitrai G, Kékesi O, Dobolyi Á, Szabó P, Fiáth R, et al. Astrocytes convert network excitation to tonic inhibition of neurons. BMC Biol. 2012;10(26):1–22.
66. Hernandez TD, Schallert T. Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102(3):318–24.
67. Hernandez-Rabaza V, Cabrera-Pastor A, Taoro-Gonzalez L, Gonzalez-Usano A, Agusti A, Balzano T, et al. Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulfora-phane by promoting M2 polarization of microglia. J Neuroinflammation. 2016;13(1):83.
68. Hill RG, Simmonds MA, Straughan DW. A comparative study of some convulsant substances as γ-aminobutyric acid antagonists in the feline cerebral cortex. Br J Pharmacol. 1973;49(1):37–51.
69. A receptors in nervous system pathologies. Curr Opin Neurobiol. 2012;22(3):552–8.
70. Hirao T, Morimoto K, Yamamoto Y, Watanabe T, Sato H, Sato K, et al. Time-dependent and regional expression of GABA transporter mRNAs following amygdala-kindled seizures in rats. Mol Brain Res. 1998;54(1):49–55.
71. Hirose S, Mitsudome A, Okada M, Kaneko S. Genetics of idiopathic epilepsies. Epilepsia. 2005;46(Suppl. 1):38–43.
72. Hutchinson PJ, O’Connell MT, Al-Rawi PG, Kett-White CR, Gupta AK, Maskell LB, et al. Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids. J Neurol Neurosurg Psychiatry. 2002;72(1):99–105.
73. Høg S, Greenwood JR, Madsen KB, Larsson OM, Frølund B, Schousboe A, et al. Structure-activity relationships of selective GABA uptake inhibitors. Curr Top Med Chem. 2006;6(17):1861–82.
74. Inglefield JR, Perry JM, Schwartz RD. Postischemic inhibition of GABA reuptake by tiagabine slows neuronal death in the gerbil hippocampus. Hippocampus. 1995;5(5):460–8.
75. Iqbal S, Baziany A, Gordon S, Wright S, Hussain M, Miyashita H, et al. Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study. Brain Res. 2002;946(2):162–70.
76. Jaenisch N, Liebmann L, Guenther M, Hübner CA, Frahm C, Witte OW. Reduced tonic inhibition after stroke promotes motor performance and epileptic seizures. Sci Report. 2016;6:26173.
77. Jardetzky O. Simple allosteric model for membrane pumps. Nature. 1966;211(5052):969–70.
78. B receptors in the hippocampus. J Neurophysiol. 2003;90(4):2690–701.
79. Johansen FF, Diemer NH. Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal CA1 pyramidal cells. Acta Neurol Scand. 1991;84(1):1–6.
80. Juhász G, Kékesi KA, Nyitrai G, Dobolyi A, Krogsgaard-Larsen P, Schousboe A. Differential effects of nipecotic acid and 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol on extracellular α-aminobutyrate levels in rat thalamus. Eur J Pharmacol. 1997;331(2–3):139–44.
81. Kaim S, Rosenstein I. Anticonvulsant properties of a new psychotherapeutic drug. Dis Nerv Syst. 1960;21(3):46–8.
82. Kang TC, Kim HS, Seo MO, Park SK, Kwon HY, Kang JH, et al. The changes in the expressions of γ-aminobutyric acid transporters in the gerbil hippocampal complex following spontaneous seizure. Neurosci Lett. 2001;310(1):29–32.
83. Kanthan R, Shuaib A, Griebel R, Miyashita H. Intracerebral human microdialysis. In vivo study of an acute focal ischemic model of the human brain. Stroke. 1995;26(5):870–3.
84. A conductances in rat neocortex. J Neurophysiol. 2005;94(3):2073–85.
85. Kersanté F, Rowley SCS, Pavlov I, Gutièrrez-Mecinas M, Semyanov A, Reul JMHM, et al. A functional role for both γ-aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus. J Physiol. 2013;591(10):2429–41.
86. Kett-White R, O’Connell MT, Hutchinson PJA, Al-Rawi PG, Gupta AK, Pickard JD, et al. Extracellular amino acid changes in patients during reversible cerebral ischaemia. Acta Neurochir Suppl. 2005;95:83–8.
87. Kim YK, Yang EJ, Cho K, Lim JY, Paik N-J. Functional recovery after ischemic stroke is associated with reduced GABAergic inhibition in the cerebral cortex: a GABA PET study. Neurorehabil Neural Repair. 2014;28(6):576–83.
88. Knake S, Hamer H, Schomburg U, Oertel W, Rosenow F. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure. 1999;8:314–7.
89. Kobayashi T, Suemasa A, Igawa A, Ide S, Fukuda H, Abe H, et al. Conformationally restricted GABA with bicyclo[3.1.0]hexane backbone as the first highly selective BGT-1 inhibitor. ACS Med Chem Lett. 2014;5(8):889–93.
90. Kong S, Cheng Z, Liu J, Wang Y. Downregulated GABA and BDNF-TrkB pathway in chronic cyclothiazide seizure model. Neural Plast. 2014;2014:9–11.
91. Kostandy BB. The role of glutamate in neuronal ischemic injury: the role of spark in fire. Neurol Sci. 2012;33(2):223–37.
92. Kragholm B, Kvist T, Madsen KK, Jørgensen L, Vogensen SB, Schousboe A, et al. Discovery of a subtype selective inhibitor of the human betaine/GABA transporter 1 (BGT-1) with a noncompetitive pharmacological profile. Biochem Pharmacol. 2013;86(4):521–8.
93. Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 2011;63(3):585–640.
94. A receptor agonist THIP is neuroprotective in organotypic hippocampal slice cultures. Brain Res. 2003;973(2):303–6.
95. Kälviäinen R. Long-term safety of tiagabine. Epilepsia. 2001;42(Suppl 1):46–9.
96. Kälviäinen R. Tiagabine. Clinical efficacy and use in epilepsy. In: Antiepileptic drugs. 5th ed. New York: Raven Press; 2002. p. 698–704.
97. Lake EMR, Chaudhuri J, Thomason L, Janik R, Ganguly M, Brown M, et al. The effects of delayed reduction of tonic inhibition on ischemic lesion and sensorimotor function. J Cereb Blood Flow Metab. 2015;35(10):1601–9.
98. Lamar CD, Hurley RA, Rowland JA, Taber KH. Post-traumatic epilepsy: review of risks, pathophysiology, and potential biomarkers. J Neuropsychiatr Clin Neurosci. 2014;26(2):108–13.
99. Lazar RM, Fitzsimmons B-F, Marshall RS, Berman MF, Bustillo MA, Young WL, et al. Reemergence of stroke deficits with midazolam challenge. Stroke. 2002;33(1):283–5.
100. Lee M, McGeer E, McGeer P. Mechanisms of GABA release from human astrocytes. Glia. 2011;59(11):1600–11.
101. Lee TS, Bjørnsen LP, Paz C, Kim JH, Spencer SS, Spencer DD, et al. GAT1 and GAT3 expression are differently localized in the human epileptogenic hippocampus. Acta Neuropathol. 2006;111(4):351–63.
102. A receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. Front Neural Circuits. 2014;8(3):1–27.
103. Lehre AC, Rowley NM, Zhou Y, Holmseth S, Guo C, Holen T, et al. Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res. 2011;95(1–2):70–81.
104. Lerma J, Herreras O, Herranz AS, Munoz D, del Rio RM. In vivo effects of nipecotic acid on levels of extracellular gaba and taurine, and hippocampal excitability. Neuropharmacology. 1984;23(5):595–8.
105. Li C, Yan Z, Yang J, Chen H, Li H, Jiang Y, et al. Neuroprotective effects of resveratrol on ischemic injury mediated by modulating the release of neurotransmitter and neuromodulator in rats. Neurochem Int. 2010a;56(3):495–500.
106. Li H, Li C, Yan Z-Y, Yang J, Chen H. Simultaneous monitoring multiple neurotransmitters and neuromodulators during cerebral ischemia/reperfusion in rats by microdialysis and capillary electrophoresis. J Neurosci Methods. 2010b;189(2):162–8.
107. Li H, Zhang N, Lin HY, Yu Y, Cai QY, Ma L, et al. Histological, cellular and behavioral assessments of stroke outcomes after photothrombosis-induced ischemia in adult mice. BMC Neurosci. 2014;15(58):1–13.
108. Lim DH, LeDue JM, Mohajerani MH, Murphy TH. Optogenetic mapping after stroke reveals network-wide scaling of functional connections and heterogeneous recovery of the peri-infarct. J Neurosci. 2014;34(49):16455–66.
109. Liu S, Wang Y, Worley PF, Mattson MP, Gaiano N. The canonical Notch pathway effector RBP-J regulates neuronal plasticity and expression of GABA transporters in hippocampal networks. Hippocampus. 2015;25(5):670–8.
110. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med. 2008;14(5): 497–500.
111. Macdonald R, Barker JL. Benzodiazepines specifically modulate GABA-mediated postsynaptic inhibition in cultured mammalian neurones. Nature. 1978;271(5645):563–4.
112. Madsen KK, Clausen RP, Larsson OM, Krogsgaard-Larsen P, Schousboe A, Steve WH. Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem. 2009;109(Suppl. 1):139–44.
113. A receptor agonist gaboxadol. J Pharmacol Exp Ther. 2011;338(1):214–9.
114. Madsen KK, White HS, Schousboe A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther. 2010;125(3):394–401.
115. A receptor α1 subunit in tremor rat hippocampus. Neurosci Lett. 2010;486(3):150–5.
116. Mathern GW, Mendoza D, Lozada A, Pretorius JK, Dehnes Y, Danbolt NC, et al. Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy. Neurology. 1999;52(3):453–72.
117. Medina-Ceja L, Sandoval-García F, Morales-Villagrán A, López-Pérez SJ. Rapid compensatory changes in the expression of EAAT-3 and GAT-1 transporters during seizures in cells of the CA1 and dentate gyrus. J Biomed Sci. 2012;19(78):1–11.
118. Meldrum BS, Horton RW. Convulsive effects of 4-deoxypyridoxine and of bicuculline in photosensitive baboons (Papio papio) and in rhesus monkeys (Macaca mulatta). Brain Res. 1971;35(2):419–36.
119. Melone M, Barbaresi P, Fattorini G, Conti F. Neuronal localization of the GABA transporter GAT-3 in human cerebral cortex: a procedural artifact? J Chem Neuroanat. 2005;30(1):45–54.
120. Melone M, Cozzi A, Pellegrini-Giampietro DE, Conti F. Transient focal ischemia triggers neuronal expression of GAT-3 in the rat perilesional cortex. Neurobiol Dis. 2003;14(1):120–32.
121. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009;10(12):861–72.
122. Nagatomo K, Ueda Y, Doi T, Takaki M, Tsuru N. Functional role of GABA transporters for kindling development in GLAST KO mice. Neurosci Res. 2007;57(2):319–21.
123. Naquet R, Soulayrol R, Dolce G, Tassinari C, Broughton R, Loeb H. First attempt at treatment of experimental status epilepticus in animals and spontaneous status epilepticus in man with diazepam. Electroencephalogr Clin Neurophysiol. 1965;18:424–7.
124. Nelson RM, Green AR, Lambert DG, Hainsworth AH. On the regulation of ischaemia-induced glutamate efflux from rat cortex by GABA; in vitro studies with GABA, clomethiazole and pentobarbitone. Br J Pharmacol. 2000;130(5):1124–30.
125. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol. 1991;196(3):257–66.
126. O’Connell AW, Fox GB, Kjøller C, Gallagher HC, Murphy KJ, Kelly J, et al. Anti-ischemic and cognition-enhancing properties of NNC-711, γ-aminobutyric acid reuptake inhibitor. Eur J Pharmacol. 2001;424(1):37–44.
127. Olsen M, Sarup A, Larsson OMOM, Schousboe A. Effect of hyperosmotic conditions on the expression of the betaine-GABA-transporter (BGT-1) in cultured mouse astrocytes. Neurochem Res. 2005;30(6–7):855–65.
128. Olsen RW, Avoli M. GABA and epileptogenesis. Epilepsia. 1997;38(4):399–407.
129. Orozco-Suarez S, Brunson KL, Feria-Velasco A, Ribak CE. Increased expression of γ-aminobutyric acid transporter-1 in the forebrain of infant rats with corticotropin-releasing hormone-induced seizures but not in those with hyperthermia-induced seizures. Epilepsy Res. 2000;42(2–3):141–57.
130. A receptors are critical targets for sedative-hypnotic drugs. J Clin Sleep Med. 2006;2(2):S12–8.
131. Ouyang C, Guo L, Lu Q, Xu X, Wang H. Enhanced activity of GABA receptors inhibits glutamate release induced by focal cerebral ischemia in rat striatum. Neurosci Lett. 2007;420(2):174–8.
132. Pabel J, Faust M, Prehn C, Wörlein B, Allmendinger L, Höfner G, et al. Development of an (S)-1-{2-[tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(S)-SNAP-5114] carba analogue inhibitor for murine γ-aminobutyric acid transporter type 4. ChemMedChem. 2012;7(7):1245–55.
133. Patrylo PR, Spencer DD, Williamson A. GABA uptake and heterotransport are impaired in the dentate gyrus of epileptic rats and humans with temporal lobe sclerosis. J Neurophysiol. 2001;85(4):1533–42.
134. Pavlov I, Walker MC. Tonic GABAA receptor-mediated signalling in temporal lobe epilepsy. Neuropharmacology. 2013;69:55–61.
135. A receptor agonists. Eur J Med Chem. 2014;84:404–16.
136. Phillis JW. CI-966, a GABA uptake inhibitor, antagonizes ischemia-induced neuronal degeneration in the gerbil. Gen Pharmacol. 1995;26(5):1061–4.
137. Pirttimaki T, Parri HR, Crunelli V. Astrocytic GABA transporter GAT-1 dysfunction in experimental absence seizures. J Physiol. 2013;591(4):823–33.
138. Pitkänen A, Löscher W, Vezzani A, Becker AJ, Simonato M, Lukasiuk K, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15(8):843–56.
139. B2 mRNA variants expression in hippocampus resected from patients with temporal lobe epilepsy. Neuroscience. 2003a;122(4):975–84.
140. B2 receptor subunits in the somatosensory cerebral cortex and thalamus of rats with absence seizures (GAERS). Epilepsy Res. 2003b;55(1–2):39–51.
141. Rassner MP, Moser A, Follo M, Joseph K, van Velthoven-Wurster V, Feuerstein TJ. Neocortical GABA release at high intracellular sodium and low extracellular calcium: an anti-seizure mechanism. J Neurochem. 2016;137(2):177–89.
142. A-receptor subtypes after focal cortical infarcts in rats: mediation by NMDA-dependent processes. J Cereb Blood Flow Metab. 2002;22(12):1463–75.
143. Richerson GB, Wu Y. Dynamic equilibrium of neurotransmitter transporters: not just for reuptake anymore. J Neurophysiol. 2003;90(3):1363–74.
144. Rowley NM, Smith MD, Lamb JG, Schousboe A, White HS. Hippocampal betaine/GABA transporter mRNA expression is not regulated by inflammation or dehydration post-status epilepticus. J Neurochem. 2011;117(1):82–90.
145. A currents. Neuroscience. 2010;167(3):644–55.
146. Schallert T, Hernandez TD, Barth TM. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Res. 1986;379(1):104–11.
147. Schallert T, Jones T, Weaver M, Shapiro L, Crippens D, Fulton R. Pharmacologic and anatomic considerations in recovery of function. Phys Med Rehabil. 1992;6(3):375–89.
148. Scharfman HE. The neurobiology of epilepsy. Curr Neuro Neurosci Rep. 2007;7(4):348–54.
149. Schijns O, Karaca Ü, Andrade P, de Nijs L, Küsters B, Peeters A, et al. Hippocampal GABA transporter distribution in patients with temporal lobe epilepsy and hippocampal sclerosis. J Chem Neuroanat. 2015;68:39–44.
150. A receptors as potential target for the treatment of temporal lobe epilepsy. Mol Neurobiol. 2016;53(8):5252–65.
151. Schousboe A. Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem Res. 2003;28(2):347–52.
152. Schousboe A, Larsson OM, Wood JD, Krogsgaard-Larsen P. Transport and metabolism of γ-aminobutyric acid in neurons and glia: implications for epilepsy. Epilepsia. 1983;24(5):531–8.
153. Schousboe A, Madsen KK, White HS. GABA transport inhibitors and seizure protection: the past and future. Future Med Chem. 2011;3(2):183–7.
154. Schousboe A, Wellendorph P, Frølund B, Clausen RP, Krogsgaard-Larsen P. Astrocytic GABA-transporters: pharmacological properties and targets for antiepileptic drugs. In: Ortega A, Schousboe A, editors. Glial amino acid transporters. Cham: Springer; in press.
155. A neurotransmission and cerebral ischemia. J Neurochem. 2001;77(2):353–71.
156. Shaju M, Abraham S. Innovations in epilepsy management - an overview. J Pharm Pharm Sci. 2013;16(4):564–76.
157. Smith MD, Saunders GW, Clausen RP, Frølund B, Krogsgaard-Larsen P, Larsson OM, et al. Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electro-graphic bursting in the medial entorhinal cortex (mEC). Epilepsy Res. 2008;79(1):6–13.
158. Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015;16(5): 249–63.
159. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1): 7–35.
160. Song I, Volynski K, Brenner T, Ushkaryov Y, Walker M, Semyanov A. Different transporter systems regulate extracellular GABA from vesicular and non-vesicular sources. Front Cell Neurosci. 2013;7(23):1–7.
161. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH, et al. The IUPHAR/ BPS Guide to Pharmacology in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res. 2016;44(D1):D1054–68.
162. Sperk G, Schwarzer C, Heilman J, Furtinger S, Reimer RJ, Edwards RH, et al. Expression of plasma membrane GABA transporters but not of the vesicular GABA transporter in dentate granule cells after kainic acid seizures. Hippocampus. 2003;13(7):806–15.
163. Spreafico R, Tassi L, Colombo N, Bramerio M, Galli C, Garbelli R, et al. Inhibitory circuits in human dysplastic tissue. Epilepsia. 2000;41(Suppl. 6):S168–73.
164. Staley K. Molecular mechanisms of epilepsy. Nat Neurosci. 2015;18(3):367–72.
165. Su J, Yin J, Qin W, Sha S, Xu J, Jiang C. Role for pro-inflammatory cytokines in regulating expression of GABA transporter type 1 and 3 in specific brain regions of kainic acid-induced status epilepticus. Neurochem Res. 2015;40(3):621–7.
166. Sutch RJ, Davies CC, Bowery NG. GABA release and uptake measured in crude synaptosomes from Genetic Absence Epilepsy Rats from Strasbourg (GAERS). Neurochem Int. 1999;34(5):415–25.
167. Thomsen C, Sørensen PO, Egebjerg J. 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol. 1997;120(6):983–5.
168. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42(Suppl. 3):8–12.
169. Trojnar MK, Małek R, Chrościńska M, Nowak S, Błaszczyk B, Czuczwar SJ. Neuroprotective effects of antiepileptic drugs. Pol J Pharmacol. 2002;54(6):557–66.
170. Ueda Y, Willmore LJ. Hippocampal γ-aminobutyric acid transporter alterations following focal epileptogenesis induced in rat amygdala. Brain Res Bull. 2000;52(5):357–61.
171. Usunoff G, Atsev E, Tchavdarov D. On the mechanisms of picrotoxin epileptic seizure (macro-and micro-electrode investigations). Electroencephalogr Clin Neurophysiol. 1969;27(4):444.
172. Vinton A, Kornberg A, Cowley M, Matkovic Z, Kilpatrick C, O’Brien T. Tiagabine-induced gener-alised non convulsive status epilepticus in patients with lesional focal epilepsy. J Clin Neurosci. 2005;12(2):128–33.
173. Vogensen SB, Jørgensen L, Madsen KK, Borkar N, Wellendorph P, Skovgaard-Petersen J, et al. Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization. J Med Chem. 2013;56(5):2160–4.
174. Wang J-G, Cai Q, Zheng J, Dong Y-S, Li J-J, Li J-C, et al. Epigenetic suppression of GADs expression is involved in temporal lobe epilepsy and pilocarpine-induced mice epilepsy. Neurochem Res. 2016;41(7):1751–60.
175. Wellendorph P, Jacobsen J, Skovgaard-Petersen J, Jurik A, Vogensen SB, Ecker G, Schousboe A, Krogsgaard-Larsen P, Clausen RP. γ-Aminobutyric acid and glycine neurotransmitter transporters. In: Sitte HH, Ecker GF, Folkers G, Mannhold R, Buschmann H, Clausen RP, editors. Transporters as drug targets. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2017. doi:10.1002/9783527679430.ch4.
176. White HS, Hunt J, Wolf HH, Swinyard EA, Falch E, Krogsgaard-Larsen P, et al. Anticonvulsant activity of the γ-aminobutyric acid uptake inhibitor N-4,4-diphenyl-3-butenyl-4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol. Eur J Pharmacol. 1993;236(1):147–9.
177. White HS, Sarup A, Bolvig T, Kristensen AS, Petersen G, Nelson N, et al. Correlation between anticonvulsant activity and inhibitory action on glial γ-aminobutyric acid uptake of the highly selective mouse γ-aminobutyric acid transporter 1 inhibitor 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and its N-alkylated anal. J Pharmacol Exp Ther. 2002;302(2):636–44.
178. White HS, Watson WP, Hansen SL, Slough S, Perregaard J, Sarup A, et al. First demonstration of a functional role for central nervous system betaine/γ-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J Pharmacol Exp Ther. 2005;312(2):866–74.
179. World Health Federation. Stroke [Internet]. 2016 [cited 2016 Sept 1]. Available from: www.world-heart-federation.org/cardiovascular-health/stroke/
180. WHO. Epilepsy Fact Sheet [Internet]. 2016a [cited 2016 Jun 30]. Available from: www.who.int/ mediacentre/factsheets/fs999/en/
181. WHO. The top 10 causes of death Fact Sheet [Internet]. 2016b [cited 2016 Jun 30]. Available from: www.who.int/mediacentre/factsheets/fs310/en/
182. Wood JD, Johnson DD, Krogsgaard-Larsen P, Schousboe A. Anticonvulsant activity of the glial-selective GABA uptake inhibitor, THPO. Neuropharmacology. 1983;22(1):139–42.
183. Wu Z, Guo Z, Gearing M, Chen G. Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzhiemer’s disease model. Nat Commun. 2014;5(4159):1–13.
184. Yang Y, Li Q, Wang CX, Jeerakathil T, Shuaib A. Dose-dependent neuroprotection with tiagabine in a focal cerebral ischemia model in rat. Neuroreport. 2000;11(10):2307–11.
185. Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia. 2012;53(Suppl 8):26–39.
186. Yunger LM, Fowler PJ, Zarevics P, Setler PE. Novel inhibitors of γ-aminobutyric acid (GABA) uptake: anticonvulsant actions in rats and mice. J Pharmacol Exp Ther. 1984;228(1):109–15.
187. Zhou Y, Holmseth S, Hua R, Lehre AC, Olofsson AM, Poblete-Naredo I, et al. The betaine-GABA transporter (BGT1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. AJP Ren Physiol. 2012;302(3):316–28.
188. Zhu XM, Ong WY. Changes in GABA transporters in the rat hippocampus after kainate-induced neuronal injury: decrease in GAT-1 and GAT-3 but upregulation of betaine/GABA transporter BGT-1. J Neurosci Res. 2004a;77(3):402–9.
189. Zhu XM, Ong WY. A light and electron microscopic study of betaine/GABA transporter distribution in the monkey cerebral neocortex and hippocampus. J Neurocytol. 2004b;33(2):233–40.